Get the Stockscreener App
0.9894
6.95%
0.0643
After Hours:
.99
0.0006
+0.06%
Invivyd Inc stock is traded at $0.9894, with a volume of 1.15M.
It is up +6.95% in the last 24 hours and up +87.17% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.9251
Open:
$0.93
24h Volume:
1.15M
Relative Volume:
0.55
Market Cap:
$112.16M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.5048
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+5.82%
1M Performance:
+87.17%
6M Performance:
+69.80%
1Y Performance:
-43.46%
1-Day Range:
$0.9251
$1.00
1-Week Range:
$0.84
$1.06
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.9894 | 112.16M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Reve - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus
Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times
Breakthrough COVID-19 Drug PEMGARDA Achieves 84% Protection in First Modern U.S. Phase 3 Trial - Stock Titan
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP By Investing.com - Investing.com South Africa
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP - Investing.com Australia
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas - marketscreener.com
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - The Manila Times
Invivyd (IVVD) Monoclonal Antibody Added to NCCN Guidelines for B-Cell Lymphomas | IVVD Stock News - GuruFocus
NCCN Guidelines Now Include PEMGARDA for B-Cell Lymphoma COVID Protection | IVVD Stock News - Stock Titan
Invivyd (IVVD) Applauds FDA's Steps to Address COVID-19 Booster Uncertainty | IVVD Stock News - GuruFocus
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - The Manila Times
Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy - Nasdaq
FDA Questions COVID Booster Benefits While Invivyd's Antibody Shows 84% Protection in Modern Trials - Stock Titan
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies By Investing.com - Investing.com Nigeria
Invivyd Holds Annual Stockholders Meeting, Elects Directors - TipRanks
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies - Investing.com
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | I - GuruFocus
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript - Insider Monkey
Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns - Investing.com Nigeria
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss - Investing.com Canada
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss By Investing.com - Investing.com South Africa
Invivyd Reports Q1 2025 Financial Results and Outlook - TipRanks
Invivyd’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Why JD.com Stock Slumped on Thursday - The Globe and Mail
INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, A - Barchart.com
Transcript : Invivyd, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strate - GuruFocus
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strategic Shift | IVVD Stock News - GuruFocus
Invivyd Reports Q1 2025 Financial Results and Highlights - TipRanks
INVIVYD Earnings Results: $IVVD Reports Quarterly Earnings - Nasdaq
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines By Investing.com - Investing.com Canada
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ - MSN
What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings - Yahoo Finance
Invivyd (IVVD) Urges FDA to Revise COVID-19 Vaccine Development - GuruFocus
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):